SEARCH

SEARCH BY CITATION

References

  • 1
    Gheorghiade M, Pang PS, Ambrosy AP, Lan G, Schmidt P, Filippatos G, Konstam M, Swedberg K, Cook T, Traver B, Maggioni A, Burnett J, Grinfeld L, Udelson J, Zannad F. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial Heart Fail Rev 2012 17 485509
  • 2
    McMurray JJ. CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin–angiotensin–aldosterone system the cornerstone of therapy for systolic heart failure Eur J Heart Fail 2011 13 929936
  • 3
    Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 2003 348 13091321
  • 4
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 1999 341 709717
  • 5
    Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 2011 364 1121
  • 6
    Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline J Clin Endocrinol Metab 2008 93 32663281
  • 7
    Epstein M, Calhoun DA. Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics J Clin Hypertens (Greenwich) 2011 13 644648
  • 8
    Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease Kidney Int 2006 70 21162123
  • 9
    Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review Am J Kidney Dis 2008 51 199211
  • 10
    Jain G, Campbell RC, Warnock DG. Mineralocorticoid receptor blockers and chronic kidney disease Clin J Am Soc Nephrol 2009 4 16851691
  • 11
    Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease Cochrane Database Syst Rev 2009 3 CD007004
  • 12
    Kosmala W, Przewlocka-Kosmala M, Szczepanik-Osadnik H, Mysiak A, O'Moore-Sullivan T, Marwick TH. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome JACC Cardiovasc Imaging 2011 4 12391249
  • 13
    Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC. Use of aldosterone antagonists in heart failure JAMA 2009 302 16581665
  • 14
    Fonarow GC, Yancy CW, Albert NM, Curtis AB, Stough WG, Gheorghiade M, Heywood JT, McBride ML, Mehra MR, O'Connor CM, Reynolds D, Walsh MN. Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF Circ Heart Fail 2008 1 98106
  • 15
    Maggioni AP, Dahlstrom U, Filippatos G, Chioncel O, Leiro MC, Drozdz J, Fruhwald F, Gullestad L, Logeart D, Metra M, Parissis J, Persson H, Ponikowski P, Rauchhaus M, Voors A, Nielsen OW, Zannad F, Tavazzi L. EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot) Eur J Heart Fail 2010 12 10761084
  • 16
    Corvol P, Michaud A, Menard J, Freifeld M, Mahoudeau J. Antiandrogenic effect of spirolactones: mechanism of action Endocrinology 1975 97 5258
  • 17
    Weber KT. Aldosterone in congestive heart failure N Engl J Med 2001 345 16891697
  • 18
    Jackson EK. Hardman JG, Limbird LE. Goodman & Gilman's: The Pharmacological Basis of Therapeutics 2001 10th ed New York McGraw-Hill 780781 Diuretics. In
  • 19
    Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension Am J Hypertens 2002 15 709716
  • 20
    Parthasarathy HK, Menard J, White WB, Young WF Jr, Williams GH, Williams B, Ruilope LM, McInnes GT, Connell JM, MacDonald TM. A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism J Hypertens 2011 29 980990
  • 21
    Funder JW. Mineralocorticoid-receptor blockade, hypertension and heart failure Nat Clin Pract Endocrinol Metab 2005 1 45
  • 22
    Kolkhof P, Borden SA. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics Mol Cell Endocrinol 2012 350 310317
  • 23
    Albaghdadi M, Gheorghiade M, Pitt B. Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes Eur Heart J 2011 32 26262633
  • 24
    Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 1999 130 461170
  • 25
    Fagart J, Hillisch A, Huyet J, Barfacker L, Fay M, Pleiss U, Pook E, Schafer S, Rafestin-Oblin ME, Kolkhof P. A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule J Biol Chem 2010 285 2993229940
  • 26
    Bärfacker L, Kuhl A, Hillisch A, Grosser R, Figueroa-Pérez S, Heckroth H, Nitsche A, Ergüden JK, Gielen-Haertwig H, Schlemmer KH, Mittendorf J, Paulsen H, Platzek J, Kolkhof P. Discovery of BAY 94-8862: a non-steroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases ChemMedChem 2012 in press dx.doi:10.1002/cmdc.201200081
  • 27
    Arhancet GB, Woodard SS, Dietz JD, Garland DJ, Wagner GM, Iyanar K, Collins JT, Blinn JR, Numann RE, Hu X, Huang HC. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines J Med Chem 2010 53 43004304
  • 28
    Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW, Hu X. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity Hypertension 2008 51 742748
  • 29
    Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC. The frequency of hyperkalemia and its significance in chronic kidney disease Arch Intern Med 2009 169 11561162